• Markets
  • icon
  • Companies
TLX · ASX

Telix Pharmaceuticals Limited (ASX:TLX)

AU$20.0

 0.07 (0.351%)
ASX:Live
17/07/2024 04:10:48 PM
Short Term Trend - Long Recent Price upgrade Recent Earnings upgrade HALO Price Momentum HALO Ords +11
Consensus Score
/10
Recommend
Target Price
Deviation
Unlock Full Consensus Insights

TLX Overview

TLX Health Scores

Short Term

Mean Revision

Neutral

Trend

Very Weak

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Very Weak

Earnings

Very Weak

Growth

Earnings

Very Weak

Dividends

Very Strong

Quality

Capital Efficiency

Very Weak

Balance Sheet

Very Weak

About TLX

Telephone

Address

Description

Telix Pharmaceuticals Ltd. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.

TLX Price Chart

Key Stats

Market Cap

AU$6.67B

PE

118.80

EV/EBITDA

50.6

Dividends Overview

DIV Yield

.0%

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 8.2 - 20.54

Trade Value (12mth)

AU$3,626,399.00

1 week

2.78%

1 month

15.87%

YTD

97.72%

1 year

69.91%

All time high

20.54

Key Fundamentals

EPS 3 yr Growth

-109.300%

EBITDA Margin

11.60%

Operating Cashflow

$24m

Free Cash Flow Return

18.80%

ROIC

4.10%

Interest Coverage

59.00

Quick Ratio

1.30

Other Data

Shares on Issue (Fully Dilluted)

332m

HALO Sector

Next Company Report Date

19-Feb-25

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

2.15

TLX Announcements

Latest Announcements

Date Announcements

11 July 24

CMS proposes payment improvement for radiopharma diagnostics

×

CMS proposes payment improvement for radiopharma diagnostics

10 July 24

Notification of cessation of securities - TLX

×

Notification of cessation of securities - TLX

04 July 24

Application for quotation of securities - TLX

×

Application for quotation of securities - TLX

04 July 24

Cleansing Notice

×

Cleansing Notice

03 July 24

Pending Release of Shares from Voluntary Escrow

×

Pending Release of Shares from Voluntary Escrow

03 July 24

Ceasing to be a substantial holder from MUFG

×

Ceasing to be a substantial holder from MUFG

03 July 24

Ceasing to be a substantial holder

×

Ceasing to be a substantial holder

02 July 24

Ceasing to be a substantial holder

×

Ceasing to be a substantial holder

02 July 24

Ceasing to be a substantial holder from MS

×

Ceasing to be a substantial holder from MS

02 July 24

Ceasing to be a substantial holder

×

Ceasing to be a substantial holder

02 July 24

Ceasing to be a substantial holder

×

Ceasing to be a substantial holder

27 June 24

Notification regarding unquoted securities - TLX

×

Notification regarding unquoted securities - TLX

27 June 24

Appendix 3Y Change in Director Interests - C Behrenbruch

×

Appendix 3Y Change in Director Interests - C Behrenbruch

27 June 24

Application for quotation of securities - TLX

×

Application for quotation of securities - TLX

27 June 24

Cleansing Notice

×

Cleansing Notice

14 June 24

Telix Elects to Withdraw from Proposed U.S. Listing

×

Telix Elects to Withdraw from Proposed U.S. Listing

13 June 24

Trading Halt

×

Trading Halt

06 June 24

Telix Launches Proposed US IPO

×

Telix Launches Proposed US IPO

03 June 24

Telix Completes TLX250-CDx (Zircaix) BLA Submission

×

Telix Completes TLX250-CDx (Zircaix) BLA Submission

31 May 24

ProstACT SELECT Study of TLX591 rADC Therapy - Positive rPFS

×

ProstACT SELECT Study of TLX591 rADC Therapy - Positive rPFS

31 May 24

Update - Application for quotation of securities - TLX

×

Update - Application for quotation of securities - TLX

28 May 24

Response to ASX Query

×

Response to ASX Query

27 May 24

Telix Submits NDA for New Prostate Cancer Imaging Agent

×

Telix Submits NDA for New Prostate Cancer Imaging Agent

22 May 24

Telix Annual General Meeting - Chairman and CEO Addresses

×

Telix Annual General Meeting - Chairman and CEO Addresses

22 May 24

Telix Annual General Meeting - Presentation

×

Telix Annual General Meeting - Presentation

TLX Fundamentals

Per Share Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.29 -0.34 0.02 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.29 -0.34 0.02 Lock Lock Lock
     Growth % Lock Lock Lock Lock -63.5 -17.4 104.9 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A 118.8 Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A 50.6 Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.20 -0.20 0.18 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.21 -0.23 0.04 Lock Lock Lock
     Growth % Lock Lock Lock Lock -86.8 -0.1 189.1 Lock Lock Lock
     Yield % Lock Lock Lock Lock -2.8 -3.1 0.4 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.01 0.25 0.46 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock -0.19 0.07 0.12 Lock Lock Lock
     Growth % Lock Lock Lock Lock -365.8 135.4 82.4 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 282 311 324 Lock Lock Lock
Basic m Lock Lock Lock Lock 282 311 319 Lock Lock Lock

Financial Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Income Statement
Sales $m Lock Lock Lock Lock 8 160 503 Lock Lock Lock
     Growth % Lock Lock Lock Lock 45.7 2,007.6 213.9 Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 51 103 263 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock -30 29 315 Lock Lock Lock
     Growth % Lock Lock Lock Lock -76.4 198.6 973.0 Lock Lock Lock
     Margin % Lock Lock Lock Lock -391.9 18.3 62.6 Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 492 82 37 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -76 -68 58 Lock Lock Lock
     Growth % Lock Lock Lock Lock -71.4 10.9 186.2 Lock Lock Lock
     Margin % Lock Lock Lock Lock -1,001.5 -42.4 11.6 Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 5 5 7 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -81 -73 52 Lock Lock Lock
     Growth % Lock Lock Lock Lock -65.0 9.9 170.4 Lock Lock Lock
     Margin % Lock Lock Lock Lock -1,069.6 -45.7 10.3 Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -99 -99 3 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock -19 5 -2 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -81 -104 5 Lock Lock Lock
     Growth % Lock Lock Lock Lock -79.4 -29.3 105.0 Lock Lock Lock
     Margin % Lock Lock Lock Lock -1,059.9 -65.0 1.0 Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -59 -64 24 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 1 14 11 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock -3 -17 -25 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 3 175 10 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -61 -71 14 Lock Lock Lock
     Growth % Lock Lock Lock Lock -3,643.6 -17.0 120.0 Lock Lock Lock
     Margin % Lock Lock Lock Lock -8.0 -0.4 0.0 Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 22 116 123 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 110 261 402 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 2 10 16 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -19 -106 -106 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 106 178 251 Lock Lock Lock
Equity $m Lock Lock Lock Lock 2 80 149 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 4 90 165 Lock Lock Lock
     Growth % Lock Lock Lock Lock -94.9 2,109.4 83.5 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -73.3 -39.9 1.3 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -3,730.8 -130.1 3.5 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -189.1 -153.8 40.1 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -190.5 -221.7 4.1 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -140.4 -136.3 18.8 Lock Lock Lock

Ratios Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Leverage
Interest Cover X Lock Lock Lock Lock -402.5 -167.0 59.0 Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 0.3 1.6 -1.8 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -903.5 -132.3 -71.0 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 1.3 2.0 1.4 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 1.2 1.9 1.3 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 46.4 67.2 54.8 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -156.2 -74.8 15.2 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.4 4.8 8.5 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 18.3 21.9 14.6 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.8 1.8 7.5 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 156.5 10.5 6.5 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.1 0.6 1.2 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.1 0.6 1.2 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock -1,303.8 -61.6 0.6 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock -90.2 -37.8 0.8 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock N/A N/A -68.8 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -73.3 -39.9 1.3 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 50.9 3.3 2.7 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -3,730.8 -130.1 3.5 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -3,730.8 -130.1 3.5 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 20.0 16.7 25.1 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 841.8 76.1 42.8 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 861.7 92.8 67.8 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 80.4 38.6 46.1 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock 781.4 54.2 21.8 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

2.15%

Value ($M)

127

Prior Change

N/A

7 Day Change

N/A

1 Month Change

-0.20%

3 Month Change

-0.20%

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

TLX Shortsell

Frequently Asked Questions

The current share price of Telix Pharmaceuticals Limited (TLX:ASX) is AU$20.0.
The 52-week high share price for Telix Pharmaceuticals Limited (TLX:ASX) is AU$20.54.
The 52-week low share price for Telix Pharmaceuticals Limited (TLX:ASX)? is AU$8.20.
The current TTM dividend payout for Telix Pharmaceuticals Limited (TLX:ASX) is 0.00.
Telix Pharmaceuticals Limited (TLX:ASX) does not pay a dividend.
Telix Pharmaceuticals Limited (TLX:ASX) has a franking level of 0.0%.
Telix Pharmaceuticals Limited (TLX:ASX) is classified in the Healthcare.
The current P/E ratio for Telix Pharmaceuticals Limited (TLX:ASX) is 118.80.